argenx SE (NASDAQ:ARGX) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of argenx SE (NASDAQ:ARGX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-two research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, eighteen have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $658.39.

ARGX has been the topic of a number of research analyst reports. William Blair raised shares of argenx from a "market perform" rating to an "outperform" rating in a research note on Friday, November 1st. Baird R W cut shares of argenx from a "strong-buy" rating to a "hold" rating in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a "hold" rating to a "sell" rating in a research note on Friday. Robert W. Baird lowered argenx from an "outperform" rating to a "neutral" rating and boosted their price objective for the stock from $515.00 to $650.00 in a research note on Friday, November 1st. Finally, Evercore ISI lifted their price objective on argenx from $675.00 to $706.00 and gave the company an "outperform" rating in a research note on Thursday, November 21st.

argenx Trading Down 2.9 %

Shares of argenx stock traded down $19.29 during trading hours on Friday, reaching $640.52. The stock had a trading volume of 483,293 shares, compared to its average volume of 312,661. The stock's 50 day moving average is $620.19 and its 200 day moving average is $555.67. argenx has a twelve month low of $349.86 and a twelve month high of $678.21. The firm has a market capitalization of $38.67 billion, a PE ratio of -727.86 and a beta of 0.59.

argenx (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The company had revenue of $588.88 million during the quarter, compared to analysts' expectations of $543.29 million. During the same quarter in the prior year, the firm posted ($1.25) EPS. As a group, sell-side analysts predict that argenx will post 2.17 earnings per share for the current year.

Institutional Trading of argenx

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd acquired a new position in shares of argenx during the 2nd quarter worth about $76,000. Cromwell Holdings LLC lifted its stake in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock worth $85,000 after purchasing an additional 66 shares during the last quarter. GAMMA Investing LLC boosted its holdings in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company's stock valued at $94,000 after purchasing an additional 56 shares in the last quarter. Blue Trust Inc. increased its stake in argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company's stock valued at $201,000 after purchasing an additional 298 shares during the last quarter. Finally, Keudell Morrison Wealth Management acquired a new stake in argenx during the third quarter worth approximately $207,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.